Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update
Enliven reported Q2 2026 financial results with a net loss of $32.5 million, or $0.49 per share, while R&D expenses increased to $29.0 million. The company ended the quarter with $895.2 million in cash and marketable securities, which is expected to fund operations into 2030. Operationally, ELVN-001 demonstrated a 61% major molecular response in Phase 1 CML patients, and the company reached alignment with the FDA on the Phase 3 ENABLE-2 trial design.
Key figures
- Mmr rate
- 61%
- Net loss
- 32500000
- Cash runway
- into 2030
- Rd expenses
- 29000000
- Mmr 24 weeks
- 48%
- Cash position
- 895200000
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.